Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women.

Cited by (481)

Items 301–400 of 481

1. Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies
   Terry A. Jacot, Meredith R. Clark, Oluwatosin Emmanuel Adedipe, Susan Godbout, Abby G. Peele, Susan Ju, Jill L. Schwartz, Andrea Ries Thurman, Gustavo F. Doncel · 2018 · Clinical and Translational Medicine
2. In Vivo Modulation of Cervicovaginal Drug Transporters and Tissue Distribution by Film-Released Tenofovir and Darunavir for Topical Prevention of HIV-1
   Karolin Hijazi, Francesco Iannelli, Anna Maria Cuppone, Delphine Desjardins, Anna Caldwell, Nathalie Dereuddre‐Bosquet, Carlo Scala, Kieron A. Smith, Indrani Mukhopadya, Bruce Frank et al. · 2020 · Molecular Pharmaceutics
3. Higher Acceptability of the Monthly Dapivirine Ring Versus Daily Oral Pre-Exposure Prophylaxis Among Adolescent Girls and Young Women in Sub-Saharan Africa in the REACH Trial
   Barbara Friedland, Erica N. Browne, Sarah T. Roberts, Kenneth Ngure, Rita Nakalega, Pippa Macdonald, Nombeko Mpongo, Siyanda Tenza, Nomsa Mhlanga, Danny Szydlo et al. · 2025 · JAIDS Journal of Acquired Immune Deficiency Syndromes
4. Beyond barriers: advances in vaginal drug delivery systems for women’s health
   Sadek Ahmed, Dina Mehana, Manal M. EL-Ashmoony · 2026 · Future Journal of Pharmaceutical Sciences
5. Refining the in vitro release test method for a dapivirine-releasing vaginal ring to match in vivo performance
   Diarmaid J. Murphy, Deanna Lim, Ryan Armstrong, Clare F. McCoy, Yahya H. Dallal Bashi, Peter Boyd, Tiffany Derrick, Patrick L. Spence, Bríd Devlin, Karl R. Malcolm · 2021 · Drug Delivery and Translational Research
6. Preventing HIV in women in Africa
   Frances Mary Cowan, Maryam Shahmanesh, Paul A. Revill, Joanna R. Busza, Euphemia Lindelwe Sibanda, Sungai T. Chabata, Natsayi Chimbindi, Tamara Choola, Owen M. Mugurungi, James Hargreaves et al. · 2025 · Nature Medicine
7. HIV‐1 testing in the context of expanding PrEP modalities
   Urvi M. Parikh, Jana L. Jacobs, Njambi Njuguna, Kristine Torjesen, John W. Mellors · 2025 · Journal of the International AIDS Society
8. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection
   Ayşe Elif Özdener-Poyraz, Tae Eun Park, Julie Kalabalik, Rachna Gupta · 2017 · Expert Review of Anti-infective Therapy
9. An Update on Antiretroviral Therapy
   Luis Menéndez‐Arias, Samara Martín-Alonso, Estrella Frutos-Beltrán · 2021 · Advances in experimental medicine and biology
10. Tenofovir vaginal film as a potential MPT product against HIV-1 and HSV-2 acquisition: formulation development and preclinical assessment in non-human primates
    Sravan Kumar Patel, Hrushikesh Bharat Agashe, Dorothy L. Patton, YVONNE T. COSGROVE SWEENEY, May A. Beamer, Craig W. Hendrix, Sharon L. Hillier, Lisa Cencia Rohan · 2023 · Frontiers in Reproductive Health
11. Evaluation of polycaprolactone matrices for sustained intravaginal delivery of a natural macromolecular microbicide, lactoferrin
    Meenakshi Pathak, A.G.A. Coombes, Manasi Jambhrunkar, Dongjie Wang, Kathryn J. Steadman · 2019 · Journal of Drug Delivery Science and Technology
12. Highlights from the 9th IAS Conference on HIV Science, 23–26 July 2017, Paris, France
    Christina K. Psomas, Tristan Barber, Sofie Rutsaert, Sabine Kinloch‐de Loes · 2017 · Journal of Virus Eradication
13. Reciprocal Modulation of Antiretroviral Drug and Steroid Receptor Function In Vitro
    Sigcinile Dlamini, Michael Kuipa, Kim Enfield, Salndave B. Skosana, John G. Woodland, Johnson M. Moliki, Alexis J. Bick, Zephne Margeret van der Spuy, Michelle F. Maritz, Chanel Avenant et al. · 2019 · Antimicrobial Agents and Chemotherapy
14. Pre-Exposure Prophylaxis (PrEP) in the Prevention of HIV: Strategies, Target Populations and Upcoming Treatments
    Ayşe Elif Özdener-Poyraz, Malgorzata Slugocki, Julie Kalabalik-Hoganson, Jayoung Han · 2020 · HIV/AIDS - Research and Palliative Care
15. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence
    Marie C. D. Stoner, Elizabeth R. Brown, Thesla Palanee‐Phillips, Leila Essop Mansoor, Tchangani Tembo, Gonasagrie Nair, Carolyne Agwau Akello, Linly Seyama, Nitesha Jeenarain, Logashvari Naidoo et al. · 2021 · AIDS and Behavior
16. Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026)
    José A. Bauermeister, Ryan C. Tingler, Clara Dominguez, Eileen Frances Dunne, Craig J. Hoesley, Ken S. Ho, Sherri Johnson, Jonathan Paul Lucas, Nicole Macagna, Elizabeth R. Brown et al. · 2021 · AIDS and Behavior
17. Translational Models to Predict Target Concentrations for Pre-Exposure Prophylaxis in Women
    Alyssa M. Lantz, Melanie R. Nicol · 2022 · AIDS Research and Human Retroviruses
18. Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions
    Ruohui Zheng, Guru Raghavendra Valicherla, Junmei Zhang, Jeremy P. Nuttall, Peter M. Silvera, Leslie J. Marshall, Philip E. Empey, Lisa Cencia Rohan · 2022 · Pharmaceutics
19. Long-acting preexposure prophylaxis: early data on roll-out in the United States
    Catherine A. Koss, Urvi M. Parikh · 2024 · Current Opinion in HIV and AIDS
20. The potential for annual long-acting HIV pre-exposure prophylaxis
    Lene Ryom · 2025 · The Lancet
21. PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study
    Nafisa J. Wara, Carey Pike, Elzette Rousseau, Pippa Macdonald, Pakama Mapukata, Bryan Leonard, Keitumetse Lebelo, Risa M. Hoffman, Catherine Orrell, Linda‐Gail Bekker et al. · 2025 · Journal of the International AIDS Society
22. Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk
    Madhuri Manohar, Mark A. Marzinke · 2019 · Clinical Biochemistry
23. Prevalence, incidence and recurrence of sexually transmitted infections in HIV ‐negative adult women in a rural South African setting
    Laura E. P. Huyveneers, Mathapelo Maphanga, Chijioke N. Umunnakwe, Larissa Bosman‐de Boer, Robert Moraba, Hugo A. Tempelman, Annemarie M. J. Wensing, Lucas E. Hermans · 2023 · Tropical Medicine & International Health
24. Associations between intravaginal practices and incidence of sexually transmitted infections and bacterial vaginosis among women enrolled in the dapivirine vaginal ring trial (The Ring Study) in southwestern Uganda: a retrospective secondary analysis
    Sylvia Kusemererwa, Eugene Ruzagira, Martin Onyango, Anita Kabarambi, Andrew Max Abaasa · 2024 · BMJ Open
25. Pre‐Exposure Prophylaxis for HIV Infection and the Role of the Women's Health Care Provider in HIV Prevention
    Leah B. Ruppe, Lisa A. Spencer, Jan M. Kriebs · 2021 · Journal of Midwifery & Women s Health
26. Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research
    Jennifer Velloza, Stephanie D. Roche, Tessa L. Concepcion, Katrina F. Ortblad · 2022 · Current Opinion in HIV and AIDS
27. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027)
    Cecilia Milford, Hariska Ramlal, Rorisang Mofokeng, Letitia Rambally Greener, Annalene M. Nel, Jennifer Ann Smit, Mariëtte Malherbe · 2024 · BMC Public Health
28. Uptake of dapivirine vaginal ring and oral pre-exposure prophylaxis among women accessing HIV prevention services in South Africa: a cohort study
    Catherine Elizabeth Martin, Hlologelo Ramatsoma, Glory Chidumwa, Pelisa Nongena, Mosa Julia Letsielo, Alison Kutywayo, Nthabiseng Koloane, Sydney Ncube, Nhlanhla Mdluli, Cornelius Nattey et al. · 2025 · The Lancet HIV
29. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial
    Brenda Gati Mirembe, Maria Valdez Cabrera, Ariane van der Straten, Rita Nakalega, Mandy Rae Cobbing, Nyaradzo Mavis Mgodi, Thesla Palanee‐Phillips, Ashley Mayo, Sufia S. Dadabhai, Leila Essop Mansoor et al. · 2022 · AIDS and Behavior
30. Update on HIV Chemoprevention
    Cherie S. Blair, Mary Catherine Cambou, Raphael J. Landovitz · 2025 · Annual Review of Medicine
31. User and healthcare provider early experiences with the PrEP ring: a quantitative study on the introduction of a new PrEP method in Eswatini
    Anita Hettema, Siphesihle Shongwe, Haley Sisel, Mxolisi Khumalo, Ncediso Gama, Nolwazi Khanyile, Buyile Mahlalela, Sindy Matse, Jill Peterson · 2025 · Journal of the International AIDS Society
32. Silver bullets and structural impediments to HIV prevention
    Kenneth Hugh Mayer, Patrick Sean Sullivan, Chris Beyrer · 2019 · The Lancet HIV
33. The dapivirine vaginal ring from the perspective of married men in Uganda
    Anita Kabarambi, Sylvia Kusemererwa, Emily A. Krogstad, Philippe Mayaud, Janet Seeley, Joseph Okello Mugisha, Mitzy Gafos · 2021 · African Journal of AIDS Research
34. Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls
    Zoë G. Baker, Marjan Javanbakht, Janell Moore, Hannah K. Brosnan, Kathleen Squires, Katherine E. Bunge, Gregory D. Zimet, Barbara Mensch, Lydia E Soto-Torres, Bill G. Kapogiannis et al. · 2021 · JAIDS Journal of Acquired Immune Deficiency Syndromes
35. Impact of Women’s Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa
    Margaret W. Gichane, Ariana W. K. Katz, Kenneth Ngure, Rachel Scheckter, Kubashni Woeber, Krishnaveni Reddy, Thelma Tauya, Chifundo Colleta Zimba, Juliane Etima, Nomvuyo Thelma Mangxilana et al. · 2021 · AIDS and Behavior
36. U.S. Black Women and Human Immunodeficiency Virus Preexposure Prophylaxis Implementation
    Karen W. Hoover, Athena P. Kourtis, Dawn K. Smith · 2022 · Obstetrics and Gynecology
37. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex
    Erica N. Browne, Kristine Torjesen, Brenda Gati Mirembe, Thesla Palanee‐Phillips, Nitesha Jeenarain, Miria Chitukuta, Marie C. D. Stoner, Leila Essop Mansoor, Krishnaveni Reddy, Thelma Tauya et al. · 2023 · AIDS Care
38. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention
    M. Melissa Peet, Vivek Agrahari, Meredith R. Clark, Gustavo F. Doncel · 2024 · Pharmaceutics
39. El papel de las intervenciones biomédicas en la prevención del VIH: la profilaxis preexposición (PrEP)
    Efrosini Zioga, Jorge Arias de la Torre, E. Patera, Beatriz Borjabad, Lizza Macorigh, Laia Ferrer · 2019 · Medicina de Familia SEMERGEN
40. Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction
    John Steytler, Charles Craig, Elna van der Ryst, Ben Van Baelen, Jeremy P. Nuttall, Neliëtte van Niekerk, John W. Mellors, Urvi M. Parikh, Carole Lorraine Wallis, for the Ring Study and the DREAM Trial Study Teams · 2022 · Clinical Infectious Diseases
41. Control groups for HIV prevention efficacy trials: what does the future hold?
    Holly Janes, Susan Buchbinder · 2023 · Current Opinion in HIV and AIDS
42. Preventing HIV among Women — A Step Forward, but Much Farther to Go
    Adaora A. Adimora · 2016 · New England Journal of Medicine
43. CHARACTERIZING THE SAUTI vAGYW HIV RISK ASSESSMENT TOOL TO MEASURE VULNERABILITY OF ADOLESCENT GIRLS AND YOUNG WOMEN IN TANZANIA
    Hannah H. Han · 2017
44. PrEP Implementation with Sexual and Gender Minority Youth: a Review on Barriers and Facilitators
    Andrew P. Barnett, Justin Unternaher, Nicholas B. Dimenstein, Natella Yurievna Rakhmanina · 2025 · Current Pediatrics Reports
45. Next Generation 3D Printed Multipurpose Intravaginal Ring For Sustained Co-Delivery of Antiretroviral Drugs and A Contraceptive Hormone
    Denali K Dahl, Rima Janusziewicz, Roopali Shrivastava, Panita Maturavongsadit, Evan Chan, Stephanie A. Montgomery, S. Rahima Benhabbour · 2025 · Pharmaceutical Research
46. The Current and Future Impact of WHO Guidance on Global HIV Pre-Exposure Prophylaxis Programs: A Narrative Review
    Fady Mishriky, Philip Chan · 2026 · Infection and Drug Resistance
47. Cancer Prevention Clinical Trials: Advances and Challenges
    Elizabeth R. Francis, Dr. Farzeen Syed, Arun Rajan, Eva M. Szabo · 2026 · Cancers
48. Design and formulation strategies to modulate drug release from implantable devices
    Elizabeth R. Magill, Masoud Adhami, Octavio E. Fandiño, Yujie Lu, Juan Domínguez‐Robles, Eneko Larrañeta · 2026 · International Journal of Pharmaceutics
49. Implantable drug delivery system: Frontiers of medicine‐engineering interdisciplinary
    Yu Zeng, Rongtai Su, Manyu Zhao, Xin Song, Ran Liu, Yuhao Zhou, Chaojuan Yang, Yanli Jiao, Xiaowei Xiang, Lingqian Chang · 2026 · Interdisciplinary medicine
50. Rectal and Vaginal
    Herman J. Woerdenbag, Jan Visser, Tina Kauss, Małgorzata Sznitowska · 2023 · Springer eBooks
51. Formulation development of dual-compartment topical inserts combining tenofovir alafenamide and elvitegravir for flexible on-demand HIV prevention
    Vivek Agrahari, M. Melissa Peet, Neelima Chandra, Prakash Ramalingam, Pardeep Kumar Gupta, Sriramakamal Jonnalagadda, Onkar Singh, Timothy J. McCormick, Gustavo F. Doncel, Meredith R. Clark · 2024 · Journal of Controlled Release
52. Engineering vaginal film platform for mucoadhesion and sustained drug release for HIV-1 prevention
    Jing Li, Sravan Kumar Patel, YVONNE T. COSGROVE SWEENEY, Dorothy L. Patton, Peter L. Anderson, Sharon L. Hillier, Lisa Cencia Rohan · 2025 · Journal of Controlled Release
53. Preferences for Long-Acting HIV Pre-Exposure Prophylaxis among Women of Reproductive Age in Low- and Middle-income Countries: A Systematic Review
    Sophia Wanjku Ngugi, Elizabeth Echoka, Vincent Omondi Were, Jacob Kazungu, Kenneth Ngure · 2025 · AIDS and Behavior
54. Pre-Exposure Prophylaxis for HIV in Primary Care and Beyond.
    Theresa Drallmeier, Ashley Meyr · 2022 · PubMed Central
55. ‘‘Ask the way from those who have walked it before”—Grandmothers’ roles in health-related decision making and HIV pre-exposure prophylaxis use among pregnant and breastfeeding women in sub-Saharan Africa
    Krishnaveni Reddy, Doreen Kemigisha, Miria Chitukuta, Sufia S. Dadabhai, Florence Mathebula, Siyanda Tenza, Thesla Palanee‐Phillips, Julia Ryan, Nicole Macagna, Petina Musara et al. · 2022 · PLoS ONE
56. Male Partner Opinions of the Dapivirine Vaginal Ring Used During an Open-Label Extension HIV Prevention Trial in KwaZulu-Natal, South Africa
    Neetha Shagan Morar, Leila Essop Mansoor, Kalendri Naidoo, Ariana W. K. Katz, Morgan Garcia, Cebo Ivan Duma, Nqobile Myeni, Themba Tshbalala, Sarita Naidoo, Elizabeth Montgomery · 2022 · JAIDS Journal of Acquired Immune Deficiency Syndromes
57. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring
    Randy M. Stalter, Tracy Qi Dong, Craig W. Hendrix, Thesla Palanee‐Phillips, Ariane van der Straten, Sharon L. Hillier, Flavia Matovu Kiweewa, Nyaradzo Mavis Mgodi, Mark A. Marzinke, Linda‐Gail Bekker et al. · 2023 · The Journal of Infectious Diseases
58. A Review and Economic Analysis of the Dapivirine Vaginal Ring as HIV Pre-Exposure Prophylaxis for Women, to Inform South African Public-Sector Guidelines
    Trudy Desirie D Leong, Jeremy Stephen Nel, Lise Jamieson, Regina B. Osih, Halima Dawood, Hasina Subedar, Michael McCaul, Leigh Francis Johnson, Karen Cohen · 2024 · JAIDS Journal of Acquired Immune Deficiency Syndromes
59. Meta-analysis of Pregnancy Events in Biomedical HIV Prevention Trials in Sub-Saharan Africa: Implications for Gender Transformative Trials
    Lara Lorenzetti, Nhi Dinh, Cason Whitcomb, Andrés Martínez, Manju Chatani, Breanne Lievense, Definate Nhamo, Catherine May Slack, Natalie T. Eley, Kathleen M. MacQueen · 2024 · AIDS and Behavior
60. Adolescent Girls and Young Women Overcoming Adherence Challenges with Vaginal and Oral PrEP Use: A Longitudinal Qualitative Study from a Crossover Trial in South Africa, Uganda, and Zimbabwe
    Mary Kate Shapley‐Quinn, Siyanda Tenza, Destry Jensen, Thelma Tauya, Lydia Mampuru, Juliane Etima, Doreen Kemigisha, Millicent Atujuna, Lydia E Soto-Torres, Sherri Johnson et al. · 2024 · AIDS and Behavior
61. Pharmacokinetics of HIV therapies in pregnant patients: an update
    Megan Neary, Andrew Owen, Adeniyi Olagunju · 2020 · Expert Opinion on Drug Metabolism & Toxicology
62. APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
    Richa Dwivedi, Youya Wang, Christopher E. Kline, Douglas K. Fischer, Zandrea Ambrose · 2022 · Frontiers in Virology
63. Canadian guidelines on HIV pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP): Discussion beyond the guidelines and commentary on the role of infectious diseases specialists
    Ameeta E. Singh, Darrell H. S. Tan, Mark Hull, Isaac I. Bogoch, Paul A. MacPherson, Cecile L. Tremblay, Stephen D. Shafran · 2018 · Journal of the Association of Medical Microbiology and Infectious Disease Canada
64. Infección por el VIH/sida: ¿El principio del fin de la primera gran pandemia contemporánea?
    Félix Gutiérrez · 2017 · Revista Clínica Española
65. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities
    Krishnaveni Reddy, Cliff Kelly, Elizabeth R. Brown, Nitesha Jeenarain, Logashvari Naidoo, Samantha S. Siva, Linda‐Gail Bekker, Gonasagrie Nair, Bonus Makanani, Lameck Chinula et al. · 2019 · AIDS
66. Next-Generation Preexposure Prophylaxis: Choices For Effective HIV Prevention
    Kenneth K. Mugwanya, Jared M. Baeten · 2019 · The Journal of Infectious Diseases
67. Introduction
    Martin H. Markowitz · 2019 · Current Opinion in HIV and AIDS
68. Present and future of HIV pre-exposure prophylaxis: a narrative review
    Andrea DE VITO, Agnese Colpani, Giulia Moi, Davide Minisci, Emanuele Focà, Andrea Calcagno, Giuseppe Nunnari, Giordano Madeddu · 2025 · Future Virology
69. Advances in drug-releasing vaginal rings
    Clare F. McCoy, Xinyu Zhao, Xin Shen, Yahya H. Dallal Bashi, Diarmaid J. Murphy, Peter Boyd, Karl R. Malcolm · 2025 · Journal of Drug Delivery Science and Technology
70. Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial
    Felix Mhlanga, Daniel W. Szydlo, Ashley J Mayo, Katherine E. Bunge, Lee Fairlie, Clemensia Nakabiito, Petina Musara, Nyaradzo Mavis Mgodi, Sufia S. Dadabhai, Rachel Scheckter et al. · 2026 · The Lancet HIV
71. Acute antagonism in three-drug combinations for vaginal HIV prevention in humanized mice
    Philippe A. Gallay, Christina M. Ramirez, Marc M. Baum · 2023 · Scientific Reports
72. Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial
    Sharana Mahomed, Nigel Garrett, Disebo Potloane, Izukanji T Sikazwe, Edmund V. Capparelli, Ishana Harkoo, Tanuja Narayansamy Gengiah, Nonhlanhla Yende‐Zuma, Farzana Osman, Leila Essop Mansoor et al. · 2023 · BMJ Open
73. Rational Design and Characterization of Trispecific Antibodies Targeting the HIV-1 Receptor and Envelope Glycoprotein
    Jinhu Liang, Linlin Zhai, Zuxin Liang, Xiaoling Chen, Yushan Jiang, Yuanlong Lin, Shiyan Feng, Yingxia Liu, Wei Zhao, Fuxiang Wang · 2023 · Vaccines
74. Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primates
    Kanika Vanshylla, Jeroen T. B. M. Tolboom, Kathryn E. Stephenson, Karin Feddes-de Boer, Annemiek Verwilligen, Sietske K. Rosendahl Huber, Lucy Rutten, Hanneke Schuitemaker, Roland C. Zahn, Dan H. Barouch et al. · 2024 · npj Vaccines
75. An updated overview on long-acting therapeutics for the prevention and treatment of human immunodeficiency virus (HIV) from a perspective of pharmaceutics
    Linh Đinh, Jason T. Blackard, Jaime Robertson, Abby Atreya, Shaina Horner, Jennifer L. Brown, Luis Alberto Gómez, Stephen Beegle, Lanesa Mahon, William C. Eades et al. · 2024 · International Journal of Pharmaceutics
76. Disclosure of oral pre-exposure prophylaxis use for HIV prevention among women enrolled in a contraceptive study: qualitative findings from Durban, South Africa
    Ivana Beesham, Mags E. Beksinska, Cecilia Milford, Leila Essop Mansoor · 2025 · Frontiers in Global Women s Health
77. HIV immunoprophylaxis: preparing the pathway from proof of concept to policy decision and use
    Johan Vekemans, William Snow, Patricia Fast, Rachel Clare Baggaley, Kundai Chinyenze, Martin Friede, Peter Godfrey‐Faussett, David C. Kaslow, Helen Rees · 2019 · The Lancet HIV
78. Evaluating the combination of emtricitabine/ tenofovir alafenamide fumarate to reduce the risk of sexually acquired HIV-1-infection in at-risk adults
    Thibault Mésplède · 2021 · Expert Opinion on Pharmacotherapy
79. Repeated administration of high‐dose depot medroxyprogesterone acetate does not alter SHIVSF 162p3 viral kinetics and tenofovir pharmacokinetics when delivered via intravaginal rings
    Priya Srinivasan, Jining Zhang, Chuong T. Dinh, Ryan S. Teller, Janet M. McNicholl, Patrick F. Kiser, Betsy C. Herold, James M. Smith · 2017 · Journal of Medical Primatology
80. Should implementation of new health technology in low- and middle-income countries follow the same guidelines as multinational drug trials?
    Joseph Niyitegeka, R Patel · 2020 · Bulletin of The Royal College of Surgeons of England
81. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa
    Jonah Leslie, Flavia Matovu Kiweewa, Thesla Palanee‐Phillips, Katherine E. Bunge, Felix Mhlanga, Betty Kamira, Jared M. Baeten, Ariana W. K. Katz, Sharon L. Hillier, Elizabeth Montgomery et al. · 2021 · BMC Women s Health
82. Production and Characterization of Anti-CCR5 siRNA-Loaded Polycaprolactone Nanoparticles for Topical Pre-exposure Prophylaxis
    Rafaela Ribeiro, Bruno Filipe Carmelino Cardoso Sarmento, José das Neves · 2021 · Methods in molecular biology
83. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention
    Krishnaveni Reddy, Florence Mathebula, Ariana W. K. Katz, Ellen H. Luecke, Siyanda Tenza, Thesla Palanee‐Phillips, Morgan Garcia, Leila Essop Mansoor, Sarita Naidoo, Neetha Shagan Morar et al. · 2022 · AIDS and Behavior
84. Recent Advances and New Challenges in Cisgender Women’s Gynecologic and Obstetric Health in the Context of HIV
    Jennifer Deese, Renee A. Heffron, Heather B. Jaspan, Lindi Masson, Jennifer A. Smit, Sengeziwe Sibeko · 2021 · Clinical Obstetrics & Gynecology
85. Safety of G2-S16 Polyanionic Carbosilane Dendrimer as Possible HIV-1 Vaginal Microbicide
    Alba Martín-Moreno, Rafael Ceña Diez, Maria Jesús Serramía, Javier López Jiménez, Rafael Gómez, María Ángeles Muñoz‐Fernández · 2022 · International Journal of Molecular Sciences
86. Controlled Drug Delivery via the Vaginal and Rectal Routes
    José das Neves, Bruno Filipe Carmelino Cardoso Sarmento · 2021
87. Comparing modelled HIV incidence estimates with empirical HIV incidence observations in high-burden HIV African epidemic settings: systematic review and meta-regression
    Oliver Stevens, Michelle Moffa, Joanne H. Hunt, Kyle Patel, Tihitna Aytenfisu, Adam N. Akullian, Rebecca L. Anderson, Peter Bock, Amelia Catharine Crampin, Sian Floyd et al. · 2026 · medRxiv
88. Long-acting pre-exposure prophylaxis preferences among pregnant and postpartum women in Kenya: results from a discrete choice experiment
    Tessa L. Concepcion, John Kinuthia, Felix Abuna Otieno, Eunita Akim, Brian P. Flaherty, Laurén Gómez, Grace C. John-Stewart, Emmaculate M. Nzove, Nancy M. Ngumbau, Jerusha N. Mogaka et al. · 2025 · AJOG Global Reports
89. Effects of test-and-treat versus preexposure prophylaxis on elimination of HIV transmission: analysis of 24 HIV prevention trials
    Anna Garratt, Abinaya Muraleetharan, Cassandra Fairhead, Andrew Martin Hill · 2025 · AIDS
90. Adherence to the Dapivirine Vaginal Ring Among Cisgender Women in Africa: Protocol for a Systematic Review and Meta‐Analysis
    Roseline Dzekem Dine, Giulia M. Muraca, Behnam Sadeghirad, Lawrence C. E. Mbuagbaw · 2025 · Health Science Reports
91. Decision-making and acceptability of subcutaneously administered broadly neutralising monoclonal antibodies for HIV prevention amongst CAPRISA 012A trial participants in Durban, South Africa
    Hilton Humphries, Hlengiwe Shozi, Zimasa Tshawe, Makhosazane N. Mdladla, Mandisa Msomi, Diane Chetty, Nqobile Myeni, Ishana Harkoo, Salim S. Abdool Karim, Sharana Mahomed · 2025 · Scientific Reports
92. Electrohydrodynamic Coating with Acyclovir PLGA Conjugate for Antiviral Functionalization of Medical Surfaces
    Tomasz Urbaniak, Witold Musiał · 2025 · International Journal of Molecular Sciences
93. User acceptability and ease of use of the MedRing, a new personalized vaginal drug delivery and monitoring device
    Joggem Veen, Marian K. Engberts, Maarten A. H. M. Wiegerinck, C. H. van der Vaart · 2026 · Expert Opinion on Drug Delivery
94. Mucosal tenofovir 1% gel stimulates cell proliferation and type I/III interferon pathways
    Sean M. Hughes, Fernanda L. Calienes, Claire Levy, Urvashi Pandey, Germán G. Gornalusse, Ross Cranston, Javier R. Lama, Jim Pickett, Rhonda M. Brand, Craig W. Hendrix et al. · 2026 · Microbiology Spectrum
95. Comparison of in-vitro release rates for vaginal systems
    Meiyu Shen, Xiaoyu Cai, Vidula Kolhatkar · 2026 · Journal of Biopharmaceutical Statistics
96. Preclinical Pharmacokinetics of a Triple-Combination Intravaginal Ring for HIV Prevention
    John A. Moss, Priya Srinivasan, Irina Butkyavichene, Manjula Gunawardana, Amalia E. Castonguay, John M. Cortez, Patricia Galván, Sofia Rivera, Jining Zhang, Chuong T. Dinh et al. · 2026 · Pharmaceutics
97. Designing Microbicides Against HIV: Innovative Rings for Young Women Urgently Needed
    Vicky Jespers, Christiana Noestlinger, Kevin K. Ariën · 2017 · Future Virology
98. PrEP: Profitieren Frauen weniger?
    Annette Haberl · 2017 · MMW - Fortschritte der Medizin
99. Disease Presentation, Recognition and Prevention
    Christopher Kwesi O. Williams · 2018 · Springer eBooks
100. Designing & Conducting Trials to Reliably Evaluate HIV Prevention Interventions
     Thomas R. Fleming, Victor G. DeGruttola, Deborah J Donnell · 2019 · Statistical Communications in Infectious Diseases